ASTH Astrana Health, Inc.

Nasdaq apollomed.net


$ 21.45 $ 0.35 (1.66 %)    

Tuesday, 18-Nov-2025 15:58:05 EST
QQQ $ 597.12 $ -7.35 (-1.22 %)
DIA $ 461.67 $ -5.02 (-1.08 %)
SPY $ 660.81 $ -5.59 (-0.84 %)
TLT $ 89.05 $ -0.03 (-0.03 %)
GLD $ 374.31 $ 2.70 (0.73 %)
$ 21.38
$ 20.98
$ 21.39 x 15
$ 21.38 x 200
$ 20.80 - $ 21.73
$ 20.78 - $ 45.16
642,056
na
1.2B
$ 1.30
$ 126.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-14-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-29-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 04-02-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 06-29-2017 03-31-2017 10-K
36 02-14-2017 12-31-2016 10-Q
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 06-29-2016 03-31-2016 10-K
40 02-16-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

TD Cowen analyst Ryan Langston maintains Astrana Health (NASDAQ:ASTH) with a Buy and lowers the price target from $40 to $35.

Core News & Articles

BTIG analyst David Larsen maintains Astrana Health (NASDAQ:ASTH) with a Buy and lowers the price target from $50 to $45.

Core News & Articles

2025 Guidance:Astrana is providing the following updated guidance for total revenue and Adjusted EBITDA for the year ending Dec...

Core News & Articles

Astrana Health (NASDAQ:ASTH) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.4...

Core News & Articles

Astrana Health (NASDAQ:ASTH) affirms FY2025 sales outlook from $3.100 billion-$3.300 billion to $3.100 billion-$3.300 billion v...

Core News & Articles

Astrana Health (NASDAQ:ASTH) sees Q3 sales of $925.000 million-$965.000 million vs $761.093 million analyst estimate.

Core News & Articles

Astrana Health (NASDAQ:ASTH) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.3...

Core News & Articles

Astrana Health (NASDAQ:ASTH) sees Q2 sales of $615.000 million-$655.000 million vs $660.68 million analyst estimate.

Core News & Articles

Astrana Health (NASDAQ:ASTH) affirms FY2025 sales outlook from $2.50 billion-$2.70 billion to $2.50 billion-$2.70 billion vs $2...

Core News & Articles

Astrana Health (NASDAQ:ASTH) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.2...

 medicare-advantage-rates-expected-to-climb-over-5-in-2026-easing-pressure-on-managed-care

CMS raises 2026 Medicare Advantage payments by 5.06%, exceeding projections and benefiting insurers focused on value-based care.

Core News & Articles

Barclays analyst Andrew Mok initiates coverage on Astrana Health (NASDAQ:ASTH) with a Equal-Weight rating and announces Pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION